Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 4, 2009, Pages 1109-1114

  Blanchet, B ^a,c   Billemont, B ^b,c   Cramard, J ^a   Benichou, A S ^a   Chhun, S ^d,e   Harcouet, L ^a   Ropert, S ^b,c,f   Dauphin, A ^a   Goldwasser, F ^b,c,f   Tod, M ^a,g,h  

^a Laboratoire de Pharmacologie Toxicologie   (France)

^b Service d'Oncologie   (France)

^c Centre d'Etude et de Recours sur les Inhibiteurs de l'Angiogénèse C E R I A   (France)

^d Institut Cochin   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITÉ DE LYON   (France)

^h UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

Author keywords

Cancer; HPLC UV; Interindividual variability and toxicity; Sorafenib; Therapeutic drug monitoring

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; ANTINEOPLASTIC AGENT; ERLOTINIB; SORAFENIB;

ACCURACY; ADULT; AGED; ARTICLE; ASTHENIA; CALIBRATION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; ELUTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEOPLASM; PLASMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SKIN MANIFESTATION; ULTRAVIOLET RADIATION; VALIDATION PROCESS; VALIDITY;

EID: 62949189153     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.02.008     Document Type: Article

References (19)

1. Patel P.H., Chaganti R.S., and Motzer R.J. Br. J. Cancer 94 (2006) 614-619
2. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. Nat. Biotechnol. 23 (2005) 329-336
3. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. Cancer Res. 64 (2004) 7099-7109
4. Moore M., Hirte H.W., Siu L., Oza A., Hotte S.J., Petrenciuc O., Cihon F., Lathia C., and Schwartz B. Ann. Oncol. 16 (2005) 1688-1694
5. Panka D.J., Wang W., Atkins M.B., and Mier J.W. Cancer Res. 66 (2006) 1611-1619
6. Takimoto C.H., and Awada A. Cancer Chemother. Pharmacol. 61 (2008) 535-548
7. European Medicine Agency, http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/H-690-en6.pdf, p. 16.
8. Strumberg D., Clark J.W., Awada A., Moore M.J., Richly H., Hendlisz A., Hirte H.W., Eder J.P., Lenz H.J., and Schwartz B. Oncologist 12 (2007) 426-437
9. Awada A., Hendlisz A., Gil T., Bartholomeus S., Mano M., de Valeriola D., Strumberg D., Brendel E., Haase C.G., Schwartz B., and Piccart M. Br. J. Cancer 92 (2005) 1855-1861
10. Clark J.W., Eder J.P., Ryan D., Lathia C., and Lenz H.J. Clin. Cancer Res. 11 (2005) 5472-5480
11. Furuse J., Ishii H., Nakachi K., Suzuki E., Shimizu S., and Nakajima K. Cancer Sci. 99 (2008) 159-165
12. Minami H., Kawada K., Ebi H., Kitagawa K., Kim Y.I., Araki K., Mukai H., Tahara M., Nakajima H., and Nakajima K. Cancer Sci. (2008) 1492-1498
13. Strumberg D., Voliotis D., Moeller J.G., Hilger R.A., Richly H., Kredtke S., Beling C., Scheulen M.E., and Seeber S. Int. J. Clin. Pharmacol. Ther. 40 (2002) 580-581
14. Jain L., Gardner E.R., Venitz J., Dahut W., and Figg W.D. J. Pharm. Biomed. Anal. 46 (2008) 362-367
15. Zhao M., Rudek M.A., He P., Hafner F.T., Radtke M., Wright J.J., Smith B.D., Messersmith W.A., Hidalgo M., and Baker S.D. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 846 (2007) 1-7
16. Lathia C., Lettieri J., Cihon F., Gallentine M., Radtke M., and Sundaresan P. Cancer Chemother. Pharmacol. 57 (2006) 685-692
17. Afify S., Rapp U.R., and Hogger P. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 809 (2004) 99-103
18. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yacobi A. Pharm Res. 17 (2000) 1551-1557
19. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000.